In recent years, the term organoid has gained attention in the fields of biomedical research, drug discovery, and personalized medicine. As a cutting-edge technology, organoids are reshaping how scientists approach disease modeling, therapeutic testing, and personalized treatment strategies. Offering a more ethical and human-relevant alternative to traditional models, they align with the FDA’s New Approach Methodologies (NAMs) and support the development of safer, more effective therapies.
Read more: What are Organoids? | From Stem Cells to Mini-Organs
Interested in Organoids – New Approach Methodologies (NAMs)? Meet Lambda Biologics at ACS Fall 2025!
We’re excited to announce that Lambda Biologics will be attending ACS Fall 2025! This year, we’ll be showcasing our ODISEI platform: an organoid-based solution that’s transforming drug discovery and precision medicine.
Our platform offers cutting-edge, non-animal testing solutions, enabling deeper insights into immune responses, tumor modeling, and drug efficacy.
We will be introducing:
- ODISEI-Oncology: Cancer Organoid-based Drug Efficacy Testing Service
- ODISEI-Disease Modeling: Human Adult Tissue & iPSC-derived Organoid-based Drug Efficacy Testing Service
- Organoid-Based Model for Functional Cosmetic Safety Testing Service
- Scalable Spatial Phenotyping Solutions
Event detail: ACS Fall 2025 – ACS Meetings and Expos
Location: Walter E. Washington Convention Center, 801 Allen Y. Lew Place NW, Washington, DC 20001, United States
Booth NO.: 2026
Website: https://www.acs.org/events/fall.html
Schedule an in-person meeting with us: https://calendar.app.google/XtKSJZfjLRnB5EEJ6
Download ODISEI brochures: https://afs.lambda-bio.com/event/conference/
Lambda Biologics’ Oncology Solutions: Patient-derived cancer organoid-based drug evaluation service
Gastric Cancer Organoid | Breast Cancer Organoid | Hepatocarcinoma Cancer Organoid | Pancreatic Cancer Organoid
